Functional significance of UDP-Glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites

Andrea S. Blevins-Primeau, Dongxiao Sun, Gang Chen, Arun K. Sharma, Carla J. Gallagher, Shantu Amin, Philip Lazaru

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Tamoxifen (TAM) is a selective estrogen receptor modulator widely used in the prevention and treatment of breast cancer. A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes. To examine whether polymorphisms in the UGT enzymes responsible for the glucuronidation of active TAM metabolites play an important role in interindividual differences in TAM metabolism, cell lines overexpressing wild-type or variant UGTs were examined for their activities against TAM metab-olites in vitro. For variants of active extrahepatic UGTs, the UGTlA817aAla/277Tyr variant exhibited no detectable glucuronidation activity against the trans isomers of either 4-OH-TAM or endoxifen. Little or no difference in TAM glucuronidating activity was observed for the uGTlA8mGly/277Cys or UGTlAlO139Lys variants compared with their wild-type counterparts. For active hepatic UGTs, the UGT2B7268Tyr variant exhibited significant (P < 0.01) 2-and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7268H1". In studies of 111 human liver microsomal specimens, the rate of O-glucuronidation against trans-4-OH-TAM and ¿rons-endoxifen was 28% (P < 0.001) and 27% (P = 0.002) lower, respectively, in individuals homozygous for the UGT2B7 TyT268TyT genotype compared with subjects with the UGT2B7 His26SHis genotype, with a significant (P < 0.01) trend of decreasing activity against both substrates with increasing numbers of the UGTZBT268"1" allele. These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy.

Original languageEnglish (US)
Pages (from-to)1892-1900
Number of pages9
JournalCancer Research
Volume69
Issue number5
DOIs
StatePublished - Mar 1 2009

Fingerprint

Glucuronosyltransferase
Tamoxifen
Genotype
Selective Estrogen Receptor Modulators
Liver
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Blevins-Primeau, Andrea S. ; Sun, Dongxiao ; Chen, Gang ; Sharma, Arun K. ; Gallagher, Carla J. ; Amin, Shantu ; Lazaru, Philip. / Functional significance of UDP-Glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. In: Cancer Research. 2009 ; Vol. 69, No. 5. pp. 1892-1900.
@article{caeb640385e54276a0051fe3097f389c,
title = "Functional significance of UDP-Glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites",
abstract = "Tamoxifen (TAM) is a selective estrogen receptor modulator widely used in the prevention and treatment of breast cancer. A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes. To examine whether polymorphisms in the UGT enzymes responsible for the glucuronidation of active TAM metabolites play an important role in interindividual differences in TAM metabolism, cell lines overexpressing wild-type or variant UGTs were examined for their activities against TAM metab-olites in vitro. For variants of active extrahepatic UGTs, the UGTlA817aAla/277Tyr variant exhibited no detectable glucuronidation activity against the trans isomers of either 4-OH-TAM or endoxifen. Little or no difference in TAM glucuronidating activity was observed for the uGTlA8mGly/277Cys or UGTlAlO139Lys variants compared with their wild-type counterparts. For active hepatic UGTs, the UGT2B7268Tyr variant exhibited significant (P < 0.01) 2-and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7268H1{"}. In studies of 111 human liver microsomal specimens, the rate of O-glucuronidation against trans-4-OH-TAM and ¿rons-endoxifen was 28{\%} (P < 0.001) and 27{\%} (P = 0.002) lower, respectively, in individuals homozygous for the UGT2B7 TyT268TyT genotype compared with subjects with the UGT2B7 His26SHis genotype, with a significant (P < 0.01) trend of decreasing activity against both substrates with increasing numbers of the UGTZBT268{"}1{"} allele. These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy.",
author = "Blevins-Primeau, {Andrea S.} and Dongxiao Sun and Gang Chen and Sharma, {Arun K.} and Gallagher, {Carla J.} and Shantu Amin and Philip Lazaru",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-08-3708",
language = "English (US)",
volume = "69",
pages = "1892--1900",
journal = "Cancer Research",
issn = "0008-5472",
number = "5",

}

Functional significance of UDP-Glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. / Blevins-Primeau, Andrea S.; Sun, Dongxiao; Chen, Gang; Sharma, Arun K.; Gallagher, Carla J.; Amin, Shantu; Lazaru, Philip.

In: Cancer Research, Vol. 69, No. 5, 01.03.2009, p. 1892-1900.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functional significance of UDP-Glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites

AU - Blevins-Primeau, Andrea S.

AU - Sun, Dongxiao

AU - Chen, Gang

AU - Sharma, Arun K.

AU - Gallagher, Carla J.

AU - Amin, Shantu

AU - Lazaru, Philip

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Tamoxifen (TAM) is a selective estrogen receptor modulator widely used in the prevention and treatment of breast cancer. A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes. To examine whether polymorphisms in the UGT enzymes responsible for the glucuronidation of active TAM metabolites play an important role in interindividual differences in TAM metabolism, cell lines overexpressing wild-type or variant UGTs were examined for their activities against TAM metab-olites in vitro. For variants of active extrahepatic UGTs, the UGTlA817aAla/277Tyr variant exhibited no detectable glucuronidation activity against the trans isomers of either 4-OH-TAM or endoxifen. Little or no difference in TAM glucuronidating activity was observed for the uGTlA8mGly/277Cys or UGTlAlO139Lys variants compared with their wild-type counterparts. For active hepatic UGTs, the UGT2B7268Tyr variant exhibited significant (P < 0.01) 2-and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7268H1". In studies of 111 human liver microsomal specimens, the rate of O-glucuronidation against trans-4-OH-TAM and ¿rons-endoxifen was 28% (P < 0.001) and 27% (P = 0.002) lower, respectively, in individuals homozygous for the UGT2B7 TyT268TyT genotype compared with subjects with the UGT2B7 His26SHis genotype, with a significant (P < 0.01) trend of decreasing activity against both substrates with increasing numbers of the UGTZBT268"1" allele. These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy.

AB - Tamoxifen (TAM) is a selective estrogen receptor modulator widely used in the prevention and treatment of breast cancer. A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes. To examine whether polymorphisms in the UGT enzymes responsible for the glucuronidation of active TAM metabolites play an important role in interindividual differences in TAM metabolism, cell lines overexpressing wild-type or variant UGTs were examined for their activities against TAM metab-olites in vitro. For variants of active extrahepatic UGTs, the UGTlA817aAla/277Tyr variant exhibited no detectable glucuronidation activity against the trans isomers of either 4-OH-TAM or endoxifen. Little or no difference in TAM glucuronidating activity was observed for the uGTlA8mGly/277Cys or UGTlAlO139Lys variants compared with their wild-type counterparts. For active hepatic UGTs, the UGT2B7268Tyr variant exhibited significant (P < 0.01) 2-and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7268H1". In studies of 111 human liver microsomal specimens, the rate of O-glucuronidation against trans-4-OH-TAM and ¿rons-endoxifen was 28% (P < 0.001) and 27% (P = 0.002) lower, respectively, in individuals homozygous for the UGT2B7 TyT268TyT genotype compared with subjects with the UGT2B7 His26SHis genotype, with a significant (P < 0.01) trend of decreasing activity against both substrates with increasing numbers of the UGTZBT268"1" allele. These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy.

UR - http://www.scopus.com/inward/record.url?scp=62449183686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449183686&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-3708

DO - 10.1158/0008-5472.CAN-08-3708

M3 - Article

VL - 69

SP - 1892

EP - 1900

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 5

ER -